Effect of Bacterial Translocation on Haemodynamic and Coagulation Parameters During Liver Transplantation

Effect of Bacterial Translocation Clinical Trial

Official title:

Effect of Bacterial Translocation on Haemodynamic and Coagulation Parameters During a Liver Transplantation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03230214
• Other study ID #: 020583
• Status: Completed
• Phase: N/A
• First received: July 20, 2017
• Last updated: January 13, 2018
• Start date: August 3, 2017
• Est. completion date: November 14, 2017

Study information

• Verified date: January 2018
• Source: Alexandria University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The present study is to demonstrate the effect of the presence of bacterial translocation detected by bacterial deoxyribonucleic acid (bactDNA) in blood and ascites using the polymerase chain reaction (PCR) on some haemodynamic and coagulation parameters during a liver transplant procedure.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: November 14, 2017
• Est. primary completion date: October 24, 2017
• Gender: All
• Age group: 20 Years to 70 Years

Eligibility

Inclusion Criteria:

• patients with liver failure undergoing liver transplantation

Exclusion Criteria:

• Age less than 18 years;

• Active overt infection;

• Patients on oral or systemic anticoagulation or with known coagulopathic disorders apart from those caused by liver failure (eg.: Protein C or S deficiency, congenital platelet disorders and congenital coagulation disorders…etc);

• Patients undergoing re-transplantation.

Related Conditions & MeSH terms

• Effect of Bacterial Translocation

Intervention

Diagnostic Test:
• PCR for bacterial translocation
samples taken from the blood and ascites of patients to search for bacterial DNA

Locations

Country	Name	City	State
Egypt	Elmoasah Hospital	Alexandria

Sponsors (1)

Lead Sponsor	Collaborator
Alexandria University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	change in the mean arterial blood pressure		at the beginning of surgery then 15 nim after dissection then 15 min after the anhepatic phase then 15 min at the reperfusion phase
Primary	antifactor X activity		at the beginning of surgery
Primary	change in the heart rate		at the beginning of surgery then 15 nim after dissection then 15 min after the anhepatic phase then 15 min at the reperfusion phase
Primary	change in the cardiac output		at the beginning of surgery then 15 nim after dissection then 15 min after the anhepatic phase then 15 min at the reperfusion phase